Financings

Palatin Technologies Inc. priced a $35 million private placement of shares and warrants.

Insmed Inc. will access a loan of up to $20 million from Hercules Technology Growth Capital Inc.

NanoViricides Inc. has raised $5 million, drawing down on its universal registered shelf offering.

GlobeImmune Inc. filed an IPO to raise $69 million to advance its cancer and infectious disease drug products.

Deals

Bristol Myers Squibb Co. and AstraZeneca plc acquired Amylin Pharmaceuticals Inc. in a $7 billion combo deal.

Isis Pharmaceuticals Inc. and Biogen Idec Inc. have entered into a second rare disease deal, targeting DM1.

Sanofi SA is optioning gene therapy products for retinal disease from Oxford Biomedica plc.

Cellworks Group Inc. and AstraZeneca will collaborate on combination therapies in tuberculosis.

Albireo signed a deal with Ferring Pharmaceuticals SA for elobixibat, for chronic idiopathic constipation.

. . . And More

Diamyd Medical AB shares dropped after its treatment for cancer pain missed the primary endpoint.

NeurogesX Inc.'s securities have been delisted on the NASDAQ Stock Market; shares trade on OTCBB.